CD86 and hydrops fetalis: Specifically, HF-MSCs and AT-MSCs were able to lower the expression of the M1 markers CD86—p < 0.001 and p < 0.05 respectively—and HLA-DR—p < 0.001 and p < 0.001, respectively—as compared with the M1 control group.